Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome

Pediatric Nephrology

Volumn 20, Issue 6, 2005, Pages 732-739

  Rao, Velidi H ^a   Lees, George E ^b   Kashtan, Clifford E ^c   Delimont, Duane C ^a   Singh, Rakesh ^d   Meehan, Daniel T ^a   Bhattacharya, Gautam ^a   Berridge, Brian R ^e   Cosgrove, Dominic ^a  

^a BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Kidney fibrosis; Matrilysin; Matrix metalloproteinase; Stromelysin 1

Indexed keywords

CASEIN; GELATINASE A; GELATINASE B; MATRILYSIN; MESSENGER RNA; STROMELYSIN;

ALPORT SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FIBROSIS; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X CHROMOSOME LINKED DISORDER; ZYMOGRAPHY;

EID: 18644382127     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1805-5     Document Type: Article

References (34)

1. Pescucci C, Longo I, Bruttini M, Mari F, Renieri A (2003) Type-IV collagen related diseases. J Nephrol 16:314-316
2. Kashtan CE (1999) Alport syndrome: An inherited disorder of renal, ocular and cochlear basement membrane. Medicine (Baltimore) 78:338-360
3. Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M (2004) Antifibrotic, nephroprotective potential of ACE inhibitor vs AT antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 19:1716-1723
4. Chen D, Jefferson B, Harvey SJ, Zheng K, Gartlay CJ, Jacobs RM, Thorner PS (2003) Cyclosporine a slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): Results from a canine model. J Am Soc Nephrol 14:14:690-698
5. Harvey SJ, Zheng K, Jefferson B, Moak P, Sado Y, Naito I, Ninomiya Y, Jacobs R, Thorner PS (2003) Transfer of the α5(IV) collagen chain gene to smooth muscle restores in vivo expression of the α6(IV) collagen chain in a canine model of Alport syndrome. Am J Pathol 162:873-885
6. Mochizuki T, Lemmink H, Mariyama M, Antignac C, Gubler M-C, Pirson Y, Verellen-Dumoulin C, Chan B, Schroder C, Smeets H, Reeders S (1994) Identification of mutations in the α3(IV) and α4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8:77-82
7. Miner JH, Sanes JR (1994) Collagen IV α3, α4, and α5 chains in rodent basal lamina: Sequence, distribution, association with laminins, and developmental switches. J Cell Biol 127:879-891
8. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG (1997) Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 15:2470-2478
9. Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, Hunter WJ, Samuelson GC (1996) Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev 10:2981-2992
10. Lees G, Helman RG, Kashtan CE, Michael AF, Homco LD, Millichamp NJ, Camacho ZT, Templeton JW, Ninomiya Y, Sado Y, Kim Y (1999) A new form of X-linked dominant hereditary nephritis in dogs. Am J Vet Res 60:373-383
11. Rheault MN, Kren SM, Thielen BK, Mess HA, Crossen JT, Thomas W, Sado Y, Kashtan CE, Segal Y (2004) Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 15:1466-1474
12. Fine LG, Ong AC, Norman JT (1993) Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur J Clin Invest 23:259-265
13. Smeglin A, Frishman WH (2004) Elastolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability. Cardiol Rev 12:141-150
14. Lopez B, Gonzalez A, Diez J (2004) Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertension 13:197-204
15. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM (2004) Membrane associated proteases and their inhibitors in tumor angiogenesis. J Clin Pathol 57:577-584
16. Rao VH, Lees GE, Kashten CE, Singh RE, Meehan DT, Rodgers K, Berridge BR, Bhattacharya G, Cosgrove D (2003) Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases) and MT1-MMP in canine X-linked Alport syndrome (XLAS). Kidney Int 63:1736-1748
17. Rodgers KD, Rao V, Meehan DT, Fager N, Gotwals P, Ryan ST, Koteliansky V, Nemori R, Cosgrove D (2003) Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. Kidney Int 63:1338-1355
18. Klahr S, Schreiner G, Ichikawa I (1998) The progression of renal disease. N Engl J Med 318:1657-1666
19. Bruijin JA, Hogendoorn PCW, Hoedenmaeker PJ, Fleuren GJ (1998) The extracellular matrix in pathology. J Lab Clin Med 111:140-149
20. Sternlicht MD, Werb Z (2000) How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 17:463-516
21. Murphy G, Knauper V, Atkinson S, Gavrilovic J, Edwards D (2000) Cellular mechanisms for focal proteolysis and the regulation of microenvironment. Fibrinolysis Proteolysis 14:165-174
22. Ries C, Petrides PD (1995) Cytokine regulation of matrix metalloproteinases activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 376:345-355
23. Liotta LA, Kohn E (2004) Anoikis: Cancer and the homeless cell. Nature 430:973-974
24. Martin SS, Vuori K (2004) Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochim Biophys Acta 1694:145-157
25. Sires UI, Murphy G, Baragi VM, Flizar CJ, Welgus HG, Senior RM (1994) Matrilysin is much more efficient than other metalloproteinases in the proteolytic inactivation of α-1 antitrypsin. Biochem Biophys Res Commun 204:613-620
26. Wilson CL, Matrician ML (1998) Matrilysin. In: Parks WC, Mecham RP (eds) Metalloproteinases. Academic Press, San Diego, pp 149-184
27. Murphy G, Cockett MI, Ward RV, Docherty AJ (1991) Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277:277-279
28. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076
29. Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A, Tschesche H (1993) Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 295:581-586
30. Miyazaki K, Umenishi F, Funahashi K, Koshikawa N, Yasumitsu H, Umeda M (1992) Activation of TIMP-2/progelatinase A complex by stromelysin. Biochem Biophys Res Commun 185:852-859
31. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y (1995) Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 270:6691-6697
32. Barille S, Bataille R, Rapp MJ, Harasseau JL, Amiot M (1999) Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 163:5723-5728
33. Crabbe T, Smith B, O'Connell J, Docherty A (1994) Human progelatinase A can be activated by matrilysin. FEBS Lett 345:14-16
34. Cosgrove DE, Rodgers KD, Meehan DT, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R (2000) Integrin α1β1 and TGF-β1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157:1649-1659